宠物医药：突破从 0 到 1，何以从 1 至 1020260629 摘要 中国宠物药品市场增长迅速，年复合增长率达 22%，需求具有刚性，贯 穿宠物生命周期。宠物老龄化加速，七岁以上老年犬占比显著提升，推 动老年病用药需求增加，养宠意识提升也增强了消费意愿。 宠物临床用药面临供给瓶颈，尤其老年病用药紧缺，长期依赖进口。行 业探索人药转化，发布《宠物临床急需使用的人用药品目录》以缓解供 需矛盾，并加速研发创新，突破慢性疾病、肿瘤等特效药研发。 国产企业在核心疫苗领域取得进展，如猫三联疫苗。瑞普生物推出国内 首个获批上市的猫三联疫苗瑞苗舒，截至 2025 年 6 月，共有 11 款国 产猫三联疫苗上市，逐步打破外资垄断。 宠物疫苗市场空间广阔，国产替代加速。国内强制免疫狂犬疫苗市场份 额约为 30-40 亿元，猫三联和犬联两种核心疫苗分别约 20 亿元左右规 模。国产企业逐步突破，形成技术集权效应。 国产猫三联疫苗在毒株匹配性和价格方面具有优势。国产疫苗毒株更适 合国内猫咪，且价格通常比进口疫苗低 20%左右，推动国产替代。 Q&A 当前我国宠物药品市场的主要特征是什么？ 我国宠物药品市场的主要特征包括需求爆发和 ...

农林牧渔行业 2025 年中期策略：宠物消费高景气，关注 周期底部抬升 20250617 摘要 中国宠物市场持续增长，2024 年整体消费增长 7.5%，猫用产品增速尤 为显著。食品作为刚需占据主导地位，主粮和营养品占比提升，健康化 和专宠专用趋势明显，推动新型主粮的接受度。 宠物食品出口受关税影响，对美出口面临挑战，企业通过海外建厂应对。 乖宝宠物泰国工厂预计年中投产，中宠加拿大产线扩建计划下半年完成， 佩蒂股份新增越南产能预计 2026 年投产，降低关税风险。 国内电商平台国产品牌表现强劲，618 购物节天猫平台成交额前五均为 国产品牌，如仙朗、兰仕、弗列加特、城市一口和麦富迪，部分品牌销 售额增速显著，如爵宴 Mediaway 同比增长 450%。 宠物动保领域呈现大单品密集上市趋势，猫三联疫苗逐步实现进口替代。 老龄化宠物增多及渗透率提升推动医药需求，诊疗药品、疫苗和驱虫药 市场规模持续扩张，复合增速可观。 生猪养殖行业政策监管趋严，供需格局向好，产能去化预期提升。2025 年 4 月能繁母猪存栏量同比微降，头部企业暂停扩产并控制出栏体重， 短期供应压力有所缓解，行业集中度提高，生产效率稳步提升。 Q ...

一股"它经济"浪潮正在席卷全国。 每经智库研究员 吴林静 王捷 每经编辑｜杨欢 《2025年中国宠物行业白皮书（消费报告）》最新数据显示，2024年我国城镇"毛孩子"数量再创新高，犬猫总数突破1.2亿只，相当于每7个城镇常住居民就 拥有一只宠物；相关消费市场规模更是突破3000亿元大关，同比增长7.5%。 宠物经济已从单纯的消费现象，跃升为各地竞相布局的新兴产业。近期，被称为"最牛风投城市"，合肥抓住这一社会心态变迁，提出"宠物友好城市"建设， 还召开了壮大宠物经济赛道的座谈会，聚焦宠物产业高质量发展。 但放眼全国宠物经济版图，把宠物经济当做一门正经产业的，早有一些城市跑在了合肥之前。 合肥入局 当宠物消费正从"吃饱穿暖"向"精致养宠"跃升，"科创之城"合肥敏锐捕捉到这一生活方式的深刻变革。其2025年市政府工作报告中，直言要"壮大宠物经济 新赛道"。 第26届亚洲宠物展 图片来源：亚宠展官方 今年3月发布的《合肥市促进宠物经济高质量发展三年行动计划（征求意见稿）》（以下简称《三年行动计划》）显示： 促进宠物医药、食品、用品、服务、医疗等多业并举协调发展。到2027年，全市宠物经济规模与效益显著提升，宠物产业 ...

Summary of Conference Call on Pet Industry and Companies Industry Overview - The pet industry is experiencing rapid growth, with an annual compound growth rate of approximately 10% driven by increasing pet ownership and the rising penetration of pet food products [2][10] - The pet medical market is projected to reach 80-90 billion by 2025, making it the second-largest segment after pet food [10] Key Companies and Their Performance 1. Guibao Pet - Guibao Pet's self-owned brand has shown strong performance, with revenue of approximately 3.5 billion, accounting for nearly 70% of total revenue, and a net profit margin of 12% [1][4] - The high-end cat food brand, Fliegate, achieved a growth rate of 100% last year and maintained the same growth rate in Q1 of this year [4] - Guibao is expected to become a leading enterprise with projected revenues nearing 25 billion and net profits around 5 billion in the medium to long term [1][4] 2. Zhongchong Co., Ltd. - Zhongchong Co., Ltd. experienced a significant growth of nearly 200%-300% from its previous low, with total revenue from its three domestic brands (Wangpi, Lingxian, and ZIP) reaching 1.4 billion last year [5] - The company aims for overseas revenue of 400 million this year, maintaining a growth rate of 50% [5][6] - The net profit margin for its North American subsidiary is reported to be between 15%-20% [6] 3. Petty Co., Ltd. - Petty's overseas business accounts for a significant portion of its operations, with a focus on exports to the U.S. [8] - Domestic revenue was approximately 290 million last year, with a target of 400-450 million this year, reflecting a growth of over 40% [9] - The company is adjusting its product lines and plans to launch new baked grain products in Q2 and Q3 [8][9] Market Dynamics and Future Outlook - The pet medical sector is characterized by a lack of dominant players, with foreign brands leading in pharmaceuticals and vaccines, indicating substantial room for domestic companies to grow [11][12] - The average medical expenses for pets have doubled due to increasing age, leading to a rigid demand for medical services [10] - Companies like Ruipuhua and KQ Bio are recommended for their comprehensive industry layouts and potential for growth in the pet medical field [13][15] Additional Insights - The overall pet industry is expected to continue expanding, with self-owned brands focusing on product innovation to enhance profitability [2] - The competitive landscape in the pet medical sector is still developing, with many local companies poised to capture market share as the industry matures [12] - Other companies to watch include Baisha Technology, Biological Shares, and Zhongmu Shares, which have varying degrees of involvement in the pet medical sector [18]

2025 年 05 月 12 日 行业周报 看好/维持 农林牧渔 农林牧渔 农业周报 20250503-20250510：粮价继续上涨，畜禽等待拐点 ◼ 走势比较 ◼ 子行业评级 | 种植业 | 看好 | | --- | --- | | 畜牧业 | 看好 | | 林业 | 中性 | | 渔业 | 中性 | | 农 产 品 加 工 | 看好 | | Ⅱ | | ◼ 推荐公司及评级 二、核心观点 行业评级及策略：粮价近期持续上涨，种植产业链景气有望触底反 转。畜禽价格低迷，产能有望高位回落。关税反制事件凸显国内农 产品供应重要性，产业发展政策环境有望持续优化，继续看好板块 投资机会。 | 中宠股份 | 买入 | | --- | --- | | 牧原股份 | 买入 | | 苏垦农发 | 买入 | 相关研究报告 <<农业周报 20250427-20250502：子 行业 1 季报分化明显，养殖相关板块 业绩增长良好>>--2025-05-07 <<年报&一季报点评：粮价低迷致业 绩承压，自营农地规模扩大>>-- 2025-04-30 <<年报&一季报点评：自主品牌高速 增长，OEM 产能布局优势突出>>-- 2025 ...

科前生物（688526.SH）：行业竞争 拖累 24 年表现，25Q1 复苏明显 事件：公司公布 2024 年报和 2025 年一季报，24 全年实现营收 9.42 亿元， yoy-11.48%，实现归母净利润 3.82 亿元，yoy-3.43%；25Q1 实现营收 2.45 亿元，yoy19.65%，实现归母净利润 1.08 亿元，yoy24.08%。 价格拖累 24 年经营表现，25Q1 复苏明显。公司 24 年全年主营兽用生物制品 实现营业收入 8.96 亿元，同比下滑 12.75%；其中销量相比 23 年增长 1.19%， 行业激烈竞争下，价格拖累了公司整体经营表现，主营业务毛利率下滑 7.72 个百分点至 65.07%。公司费用管控持续优化，24 年公司四项费用率合计 21.25%，相比 23 年下降 1.68 个百分点，主要由销售费用的缩减带来（同比 下降 2.44 个百分点）。 随下游养殖盈利回暖，动保需求逐步复苏，公司 25Q1 收入业绩明显回暖，25Q1 销售收入同比增长 19.65%，销售毛利率 65.88%，相比 24 年回升 2.12 个百 分点。四项费用率在销售费用的持续优化下，同比 ...

1 、 《 PEEK材料产业链梳理，下一个千亿级赛道？ 》摘要 ■ PEEK的自润滑性和耐高温性能使其成为机器人驱动系统中的理想材料，减少摩擦和噪音，延长使 用寿命。 ■ 由于其优异的耐热、绝缘及耐腐蚀性，PEEK适合用于电子设备的支撑结构，尤其是在特殊环境下 工作的机器人中，如医疗和航天机器人。 ■ PEEK的核心原料是二氟二苯甲酮（DFBP），这类原料的生产技术掌握在少数企业手中，全球产能 集中度高。 2、 《 宠物经济虽热，难掩动物保健行业颓势 》摘要 ■ 2024年中国的宠物市场规模预计突破3000亿元，且宠物用药对安全性和有效性有更高要求，尤其 是猫三联和犬四联疫苗的国产化进程正在加速。 ■ 瑞普生物在宠物用疫苗领域表现突出，特别是打破了进口品牌对猫三联疫苗的垄断，取得了一定的 市场份额。 ■ 大型养殖集团如温氏股份、牧原股份等已经开始布局兽药和疫苗业务，这使得独立的动物保健企业 面临着前所未有的压力。 ■ 随着大型养殖企业自建兽药产能，并通过集中采购提高议价能力，独立兽药公司的市场空间将被进 一步压缩。 3、 《 关税战，先把宠物经济"打爆了" 》摘要 ■ 乖宝宠物通过高效的成本管控和规模效应，推 ...

重视研发持续创新，新品储备充足厚积薄发 2024 年公司研发投入1.79 亿元，占营业收入14.25%。报告期内公司独家取得羊布鲁氏菌病活疫苗 （Rev.1 株）等多个重要单品生产文号，并申报全球第一个猫传腹mRNA 疫苗。非瘟疫苗方面，公司非 瘟亚单位疫苗安全性及有效性达到农业农村部《非洲猪瘟亚单位疫苗免疫效力评价指导原则》规定标 准，目前正有序推进评审。公司重视研发创新，新品储备充足，长期成长动能强劲。 风险提示：猪价上涨不及预期，非瘟疫苗研发不及预期，市场竞争加剧。 业绩短期承压，持续创新厚积薄发，维持"买入"评级公司发布2024 年年报及2025 年一季报，2024 年营 收12.55 亿元（-21.45%），归母净利润1.09 亿元（-61.58%），归母净利润下滑系行业竞争加剧，产品 价格下降、毛利下滑叠加公司继续保持高强度研发投入。2025Q1 营收3.52 亿元（+1.06%），归母净利 润0.76 亿元（-27.57%）。行业竞争加剧，公司短期业绩承压，我们下调公司2025-2026 年盈利预测，新 增2027 年盈利预测，预计公司2025-2027 年归母净利润分别为2.51/3.48/4 ...

Investment Rating - The overall industry rating is positive, with expectations for higher returns compared to the CSI 300 index in the next six months [52]. Core Views - The agricultural product prices have shown a divergence recently, with grain prices continuing to rise while livestock prices have stabilized after an initial increase. The importance of domestic food security has been highlighted by tariff countermeasures, and the policy environment for industry development is expected to continue improving, indicating ongoing investment opportunities in the sector [5][18]. - The livestock industry chain is experiencing stagnation in production capacity growth, with the valuation of the sector at a low point, suggesting long-term investment opportunities. The average price of live pigs is currently 14.95 yuan/kg, reflecting a slight decrease from the previous week [5][19]. - The poultry sector is witnessing fluctuations in chicken prices, with the average price for white feather broilers at 3.73 yuan/kg, down 0.02 yuan from last week. The industry is advised to monitor the impacts of avian influenza and tariff countermeasures [21][20]. Summary by Sections Livestock Industry Chain - **Pork**: The production capacity growth has stagnated, and the sector's valuation is at a historical low, indicating potential long-term investment value. The average price of live pigs is 14.95 yuan/kg, down 0.02 yuan from last week [5][19]. - **Poultry**: The average price for white feather broilers is 3.73 yuan/kg, down 0.02 yuan from last week. The industry is advised to monitor the impacts of avian influenza and tariff countermeasures [21][20]. - **Eggs**: The average price for yellow chickens has shown a slight increase, with prices at 10.69 yuan/kg for Lihua yellow chickens, up 0.32 yuan from last month [21]. Planting Industry Chain - **Seed Industry**: The recent announcement of 99 genetically modified corn and soybean varieties pending approval indicates a significant expansion in domestic GM crop varieties, which is expected to enhance agricultural production efficiency [22]. - **Grain Prices**: Recent increases in grain prices, with corn at 2291 yuan/ton and wheat at 2434 yuan/ton, suggest potential investment opportunities in the context of reduced imports and tariff measures against U.S. agricultural products [22][11]. Recommended Companies - The report recommends several companies for investment, including: - Zhongchong Co., Ltd. (Buy) - Muyuan Foods Co., Ltd. (Buy) - Suqian Agricultural Development Co., Ltd. (Buy) [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance is under short-term pressure due to intensified industry competition, declining product prices, and reduced gross margins, alongside continued high R&D investment. However, the company has a strong pipeline of new products that are expected to contribute positively to future growth [4][5][6] Financial Performance Summary - In 2024, the company reported revenue of 1.255 billion yuan, a decrease of 21.45% year-on-year, and a net profit attributable to shareholders of 109 million yuan, down 61.58% year-on-year. The decline in net profit is attributed to increased competition in the industry [4][7] - For Q1 2025, the company achieved revenue of 352 million yuan, an increase of 1.06% year-on-year, while the net profit attributable to shareholders was 76 million yuan, a decrease of 27.57% year-on-year [4] - The company has revised its profit forecasts for 2025-2026 downwards and introduced a new forecast for 2027, expecting net profits of 251 million yuan, 348 million yuan, and 448 million yuan for 2025, 2026, and 2027 respectively [4][7] Market Position and Product Pipeline - The company maintains a solid market share for its major products, with a 23% market share for its pig circovirus vaccine and a 40% market share for its brucellosis vaccine. Several major products are expected to be launched in 2024, contributing to revenue growth in 2025 [5][6] - The company has a strong focus on R&D, with 179 million yuan invested in 2024, representing 14.25% of its revenue. It has obtained production licenses for several important vaccines and is progressing with the development of a novel mRNA vaccine for cats [6] Financial Metrics and Valuation - The company's gross margin for 2024 was 53.86%, and the net margin was 8.30%, reflecting a decline of 5.33 percentage points and 9.04 percentage points respectively. For Q1 2025, the gross margin was 54.53% and the net margin was 21.96% [5] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.22 yuan, 0.31 yuan, and 0.40 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 31.4, 22.6, and 17.5 [4][7]